Fri Mar 07 02:40:00 UTC 2025: **FDA Nominee Makary Vows Science-Based Approach, Defers on Controversial Issues**

Washington D.C. – Dr. Marty Makary, President Trump’s nominee to lead the Food and Drug Administration (FDA), pledged a science-focused approach to regulation during his Senate confirmation hearing Thursday. While promising to restore public trust in the agency, Makary avoided direct answers on several contentious issues, including access to the abortion pill mifepristone and recent FDA staff firings.

Testifying before the Senate Health, Education, Labor, and Pensions Committee, Makary emphasized the importance of open scientific discourse, stating, “I don’t… believe in censorship of scientific opinions.” He cited declining public trust as a factor limiting the effectiveness of even life-saving treatments.

Facing questions regarding mifepristone, Makary committed to a thorough review of existing data and consultations with FDA scientists before making any policy decisions. He declined to state whether he would maintain or restrict access to the medication, prompting criticism from Senator Maggie Hassan (D-NH) for his lack of a clear position.

Similarly, Makary sidestepped questions about the cancellation of a key vaccine advisory committee meeting, explaining he was not involved in the decision but pledged a review of the committee’s operations and ethics policies, citing concerns about potential conflicts of interest between industry and regulators. However, he did assure the committee that the VRBPAC meeting would reconvene if he were confirmed.

While avoiding direct comment on the recent FDA staff reductions, Makary promised a comprehensive assessment of agency staffing if confirmed as commissioner. He also addressed high prescription drug prices, suggesting that increased access to over-the-counter medications and curbing patent system abuse could help lower costs. Furthermore, he expressed a commitment to investigating the impact of food-related chemicals on health, particularly in relation to childhood obesity and the rise of early-onset Alzheimer’s disease.

Makary’s testimony highlighted a focus on restoring public trust through transparency and scientific rigor, while simultaneously leaving many key policy decisions pending further review. The Senate will now consider his nomination.

Read More